Literature DB >> 10728796

Drug-induced liver diseases.

D Larrey1.   

Abstract

Drug-induced liver injuries make up a persisting and challenging problem for physicians, health agencies and pharmaceutical firms. The clinical expression is polymorphous, acute hepatitis being predominant. The diagnosis is frequently difficult because of the absence of specific signs in most cases and mainly relies on the exclusion of other causes. The diagnosis should be particularly evoked in patients over 50 yr who are taking many drugs, after viral infections have been ruled out. Acute hepatocellular hepatitis is particularly severe because of the risk of fulminant hepatitis or of a more insidious course leading to cirrhosis. Cross hepatotoxicity can sometimes occur. One should avoid re-administration of not only the causative agents but also of other drugs belonging to the same family or having a related chemical structure. The prediction of the hepatotoxicity of new drugs must be improved. Investigations would be particularly useful for drugs having critical chemical structures and belonging to families with an established history of hepatotoxicity.

Entities:  

Mesh:

Year:  2000        PMID: 10728796     DOI: 10.1016/s0168-8278(00)80417-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  37 in total

1.  Hepatic adverse drug reactions: a case/non-case study in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Alfredo Cocci; Francesco Salvo; Barbara Ros; Ilaria Meneghelli; Mauro Venegoni; Paola Maria Cutroneo; Alberto Vaccheri; Gianpaolo Velo; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2006-11-22       Impact factor: 2.953

2.  Drug-induced liver injury associated with ezetimibe therapy.

Authors:  Qiang Liu; Hillel Tobias; Lydia M Petrovic
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

3.  Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?

Authors:  Stefano Ballestri; Amedeo Lonardo; Luisa Losi; Elisa Pellegrini; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2008-07-17       Impact factor: 3.397

4.  Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies.

Authors:  Aileen Smith; John Dillon
Journal:  BMJ Case Rep       Date:  2009-09-02

Review 5.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

6.  Hypertransaminasemia in childhood as a marker of genetic liver disorders.

Authors:  Raffaele Iorio; Angela Sepe; Antonietta Giannattasio; Francesco Cirillo; Angela Vegnente
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

7.  S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice.

Authors:  Jia Xiao; Emily C Liong; Ming-Tat Ling; Yick-Pang Ching; Man-Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2011-06-18       Impact factor: 5.614

Review 8.  Mechanisms of drug-induced liver injury.

Authors:  Michael P Holt; Cynthia Ju
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

9.  Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.

Authors:  Paul B Watkins; Louise M Dube; Karen Walton-Bowen; Christopher M Cameron; Linda E Kasten
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  DILI: New Insights into Diagnosis and Management.

Authors:  Thanh Tran; William M Lee
Journal:  Curr Hepat Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.